{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:11:50Z","timestamp":1783350710383,"version":"3.54.6"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Almirall SpA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13555-026-01676-3","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:50:48Z","timestamp":1771505448000},"page":"1795-1812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Psychological Well-Being of Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab: 28-Week Interim Results from a Multicenter Observational Study in Italy Using the DASS-21 Questionnaire, the BLUE Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8301-9206","authenticated-orcid":false,"given":"Emanuele","family":"Trovato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7752-4337","authenticated-orcid":false,"given":"Claudio","family":"Bonifati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-1406","authenticated-orcid":false,"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9912-3611","authenticated-orcid":false,"given":"Massimiliano","family":"Scalvenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1938-8581","authenticated-orcid":false,"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-1554","authenticated-orcid":false,"given":"Aldo","family":"Cuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1589-867X","authenticated-orcid":false,"given":"Vincenzo","family":"Panasiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7170-3972","authenticated-orcid":false,"given":"Antonio Giovanni","family":"Richetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-6779","authenticated-orcid":false,"given":"Gianluca","family":"Pagnanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5237-0463","authenticated-orcid":false,"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2227-581X","authenticated-orcid":false,"given":"Franco","family":"Rongioletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1610-9249","authenticated-orcid":false,"given":"Francesca","family":"Satolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6162-2004","authenticated-orcid":false,"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9163-9691","authenticated-orcid":false,"given":"Alessandro","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-5175","authenticated-orcid":false,"given":"Marco","family":"Galluzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lasagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2586-2558","authenticated-orcid":false,"given":"Giovanna","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4127-0141","authenticated-orcid":false,"given":"Marco","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3108-4123","authenticated-orcid":false,"given":"Emanuele","family":"Cozzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-8779","authenticated-orcid":false,"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6800-3695","authenticated-orcid":false,"given":"Marina","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6355-2588","authenticated-orcid":false,"given":"Maria Rita","family":"Bongiorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-2045","authenticated-orcid":false,"given":"Francesca","family":"Prignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8961-7108","authenticated-orcid":false,"given":"Vito","family":"Di Lernia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9050-9657","authenticated-orcid":false,"given":"Franca","family":"Taviti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-5877","authenticated-orcid":false,"given":"Severino","family":"Persechino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"De Pasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Colonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3070-4071","authenticated-orcid":false,"given":"Marina","family":"Talamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-2557","authenticated-orcid":false,"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"1676_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180","volume":"8","author":"G Damiani","year":"2021","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med. 2021;8:743180. https:\/\/doi.org\/10.3389\/fmed.2021.743180.","journal-title":"Front Med"},{"key":"1676_CR2","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1007\/s13555-023-01060-5","volume":"13","author":"PC Luna","year":"2023","unstructured":"Luna PC, Chu C-Y, Fatani M, et al. Psychosocial burden of psoriasis: a systematic literature review of depression among patients with psoriasis. Dermatol Ther (Heidelb). 2023;13:3043\u201355. https:\/\/doi.org\/10.1007\/s13555-023-01060-5.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1676_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1499714","volume":"15","author":"L Huang","year":"2024","unstructured":"Huang L, Feng Z, Xu C, et al. Stigma and psychological health in psoriasis patients based on the dual-factor model of mental health: the chain mediating roles of social appearance anxiety and alexithymia. Front Psychiatry. 2024;15:1499714. https:\/\/doi.org\/10.3389\/fpsyt.2024.1499714.","journal-title":"Front Psychiatry"},{"key":"1676_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115078","volume":"321","author":"L Liu","year":"2023","unstructured":"Liu L, Lin N, Yu Y, et al. Epidemiology of mental health comorbidity in patients with psoriasis: an analysis of trends from 1986 to 2019. Psychiatr Res. 2023;321:115078. https:\/\/doi.org\/10.1016\/j.psychres.2023.115078.","journal-title":"Psychiatr Res"},{"key":"1676_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00403-018-1832-x","volume":"310","author":"Z Kwan","year":"2018","unstructured":"Kwan Z, Bong YB, Tan LL, et al. Determinants of quality of life and psychological status in adults with psoriasis. Arch Dermatol Res. 2018;310:443\u201351. https:\/\/doi.org\/10.1007\/s00403-018-1832-x.","journal-title":"Arch Dermatol Res"},{"key":"1676_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","volume":"22","author":"A Thatiparthi","year":"2021","unstructured":"Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ. Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol. 2021;22:425\u201342. https:\/\/doi.org\/10.1007\/s40257-021-00603-w.","journal-title":"Am J Clin Dermatol"},{"key":"1676_CR7","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/bjd.15531","volume":"177","author":"IYK Iskandar","year":"2017","unstructured":"Iskandar IYK, Ashcroft DM, Warren RB, et al. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. Br J Dermatol. 2017;177:1410\u201321. https:\/\/doi.org\/10.1111\/bjd.15531.","journal-title":"Br J Dermatol"},{"key":"1676_CR8","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1111\/jdv.15012","volume":"32","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Armstrong AW, Han C, et al. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase\u00a03 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018;32:1940\u20139. https:\/\/doi.org\/10.1111\/jdv.15012.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1676_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1684\/ejd.2021.4150","volume":"31","author":"A Campanati","year":"2021","unstructured":"Campanati A, Diotallevi F, Radi G, et al. Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study. Eur J Dermatol. 2021;31:630\u20137. https:\/\/doi.org\/10.1684\/ejd.2021.4150.","journal-title":"Eur J Dermatol"},{"key":"1676_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-29","volume":"1","author":"RP Snaith","year":"2003","unstructured":"Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes. 2003;1:29. https:\/\/doi.org\/10.1186\/1477-7525-1-29.","journal-title":"Health Qual Life Outcomes"},{"key":"1676_CR11","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3712","volume":"101","author":"M Talamonti","year":"2021","unstructured":"Talamonti M, Malara G, Natalini Y, et al. Secukinumab improves patient perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study. Acta Derm Venereol. 2021;101:adv00422. https:\/\/doi.org\/10.2340\/00015555-3712.","journal-title":"Acta Derm Venereol"},{"key":"1676_CR12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase\u00a03 trials. Lancet. 2017;390:276\u201388. https:\/\/doi.org\/10.1016\/S0140-6736(17)31279-5.","journal-title":"Lancet"},{"key":"1676_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13175240","volume":"13","author":"E Trovato","year":"2024","unstructured":"Trovato E, Dragotto M, Capalbo E, Cartocci A, Rubegni P, Calabrese L. Uncovering the differences: how DLQI and WHO-5 scores vary in moderate-to-severe psoriasis patients treated with tildrakizumab 100\u00a0mg vs. 200\u00a0mg? J Clin Med. 2024;13:5240. https:\/\/doi.org\/10.3390\/jcm13175240.","journal-title":"J Clin Med"},{"key":"1676_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.21580\/pjpp.v7i2.11802","volume":"7","author":"Q Nada","year":"2022","unstructured":"Nada Q, Herdiana I, Andriani F. Testing the validity and reliability of the Depression Anxiety Stress Scale (DASS)-21 instrument for individuals with psychodermatology. Psikohumaniora J Penelit Psikol. 2022;7:153\u201368. https:\/\/doi.org\/10.21580\/pjpp.v7i2.11802.","journal-title":"Psikohumaniora J Penelit Psikol"},{"key":"1676_CR15","doi-asserted-by":"publisher","unstructured":"Lovibond PF, Lovibond SH. Depression anxiety and stress scales. 2015. https:\/\/doi.org\/10.1037\/t39835-000.","DOI":"10.1037\/t39835-000"},{"key":"1676_CR16","doi-asserted-by":"publisher","unstructured":"Lovibond SH, Lovibond PF. Depression anxiety stress scales. 2011 https:\/\/doi.org\/10.1037\/t01004-000.","DOI":"10.1037\/t01004-000"},{"key":"1676_CR17","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1177\/1073191119887449","volume":"28","author":"C Zanon","year":"2021","unstructured":"Zanon C, Brenner RE, Baptista MN, et al. Examining the dimensionality, reliability, and invariance of the Depression, Anxiety, and Stress Scale-21 (DASS-21) across eight countries. Assessment. 2021;28:1531\u201344. https:\/\/doi.org\/10.1177\/1073191119887449.","journal-title":"Assessment"},{"key":"1676_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/pon.3055","volume":"22","author":"L Sharp","year":"2013","unstructured":"Sharp L, Carsin A-E, Timmons A. Associations between cancer-related financial stress and strain and psychological well-being among individuals living with cancer. Psychooncology. 2013;22:745\u201355. https:\/\/doi.org\/10.1002\/pon.3055.","journal-title":"Psychooncology"},{"key":"1676_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1282249","volume":"14","author":"SA Abualhamael","year":"2023","unstructured":"Abualhamael SA, Baig M, Alghamdi W, Gazzaz ZJ, Al-Hayani M, Bazi A. Quality of life, stress, anxiety and depression and associated factors among people with type\u00a02 diabetes mellitus in Western region Saudi Arabia. Front Psychiatry. 2023;14:1282249. https:\/\/doi.org\/10.3389\/fpsyt.2023.1282249.","journal-title":"Front Psychiatry"},{"key":"1676_CR20","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00296-019-04376-8","volume":"39","author":"S Milutinovic","year":"2019","unstructured":"Milutinovic S, Veljkovic K, Zlatanovic M, Radunovic G, Damjanov N. Depression\/anxiety symptoms in axial spondyloarthritis and psoriatic arthritis patients in Serbia: a pilot study. Rheumatol Int. 2019;39:1595\u2013605. https:\/\/doi.org\/10.1007\/s00296-019-04376-8.","journal-title":"Rheumatol Int"},{"key":"1676_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.12788\/cutis.1130","volume":"114","author":"B Temel","year":"2024","unstructured":"Temel B, Orenay OM, Karaosmanoglu N. Eating disorder risk factors and the impact of obesity in patients with psoriasis. Cutis. 2024;114:164\u20138. https:\/\/doi.org\/10.12788\/cutis.1130.","journal-title":"Cutis"},{"key":"1676_CR22","unstructured":"Ilumetri, SmPC [Internet]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ilumetri-epar-product-information_it.pdf. Accessed 9 Sept 2025."},{"key":"1676_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"key":"1676_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000376585","volume":"84","author":"CW Topp","year":"2015","unstructured":"Topp CW, \u00d8stergaard SD, S\u00f8ndergaard S, Bech P. The WHO-5 well-being index: a systematic review of the literature. Psychother Psychosom. 2015;84:167\u201376. https:\/\/doi.org\/10.1159\/000376585.","journal-title":"Psychother Psychosom"},{"key":"1676_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis\u2014oral therapy with a new retinoid. Dermatologica. 1978;157:238\u201344. https:\/\/doi.org\/10.1159\/000250839.","journal-title":"Dermatologica"},{"key":"1676_CR26","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/jdv.12861","volume":"29","author":"MJ Simpson","year":"2015","unstructured":"Simpson MJ, Chow C, Morgenstern H, Luger TA, Ellis CN. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician\u2019s Global Assessment, Psoriasis Area and Severity Index and Static Physician\u2019s Global Assessment. J Eur Acad Dermatol Venereol. 2015;29:1415\u201320. https:\/\/doi.org\/10.1111\/jdv.12861.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1676_CR27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2340\/00015555-1246","volume":"92","author":"NQ Phan","year":"2012","unstructured":"Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92:502\u20137. https:\/\/doi.org\/10.2340\/00015555-1246.","journal-title":"Acta Derm Venereol"},{"key":"1676_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-79","volume":"1","author":"K Webster","year":"2003","unstructured":"Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79. https:\/\/doi.org\/10.1186\/1477-7525-1-79.","journal-title":"Health Qual Life Outcomes"},{"key":"1676_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.sleep.2004.07.006","volume":"6","author":"RD Hays","year":"2005","unstructured":"Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med. 2005;6:41\u20134. https:\/\/doi.org\/10.1016\/j.sleep.2004.07.006.","journal-title":"Sleep Med"},{"key":"1676_CR30","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1111\/jdv.19468","volume":"37","author":"S Berenguer-Ruiz","year":"2023","unstructured":"Berenguer-Ruiz S, Aparicio-Dom\u00ednguez M, Herranz-Pinto P, et al. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24\u2009weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. J Eur Acad Dermatol Venereol. 2023;37:2517\u201325. https:\/\/doi.org\/10.1111\/jdv.19468.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1676_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2200872","volume":"34","author":"N Bhatia","year":"2023","unstructured":"Bhatia N, Heim J, Schenkel B, Vasquez JG. Quality of life and patient-reported symptoms in a phase\u00a04, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: week\u00a028 interim analysis. J Dermatol Treat. 2023;34:2200872. https:\/\/doi.org\/10.1080\/09546634.2023.2200872.","journal-title":"J Dermatol Treat"},{"key":"1676_CR32","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1111\/jdv.15862","volume":"33","author":"A Blauvelt","year":"2019","unstructured":"Blauvelt A, Sofen H, Papp K, et al. Tildrakizumab efficacy and impact on quality of life up to 52\u00a0weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol. 2019;33:2305\u201312. https:\/\/doi.org\/10.1111\/jdv.15862.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1676_CR33","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-2-6","volume":"10","author":"M Burlando","year":"2021","unstructured":"Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021;10:2021-2\u20136. https:\/\/doi.org\/10.7573\/dic.2021-2-6.","journal-title":"Drugs Context"},{"key":"1676_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15488","author":"G Caldarola","year":"2022","unstructured":"Caldarola G, Galluzzo M, Bernardini N, et al. Tildrakizumab in moderate-to-severe plaque psoriasis: a multicenter, retrospective, real-life study. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/dth.15488.","journal-title":"Dermatol Ther"},{"key":"1676_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ph16040526","volume":"16","author":"E Campione","year":"2023","unstructured":"Campione E, Lambiase S, Gaeta Shumak R, et al. A real-life study on the use of tildrakizumab in psoriatic patients. Pharmaceuticals (Basel). 2023;16:526. https:\/\/doi.org\/10.3390\/ph16040526.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1676_CR36","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1111\/jdv.19229","volume":"37","author":"A Costanzo","year":"2023","unstructured":"Costanzo A, Llamas-Velasco M, Fabbrocini G, et al. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. J Eur Acad Dermatol Venereol. 2023;37:2004\u201315. https:\/\/doi.org\/10.1111\/jdv.19229.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1676_CR37","doi-asserted-by":"publisher","DOI":"10.1159\/000519924","author":"KA Drerup","year":"2021","unstructured":"Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology. 2021. https:\/\/doi.org\/10.1159\/000519924.","journal-title":"Dermatology"},{"key":"1676_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092631","volume":"11","author":"M Galluzzo","year":"2022","unstructured":"Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis. J Clin Med. 2022;11:2631. https:\/\/doi.org\/10.3390\/jcm11092631.","journal-title":"J Clin Med"},{"key":"1676_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15818","volume":"35","author":"L Mastorino","year":"2022","unstructured":"Mastorino L, Cariti C, Susca S, et al. Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement. Dermatol Ther. 2022;35:e15818. https:\/\/doi.org\/10.1111\/dth.15818.","journal-title":"Dermatol Ther"},{"key":"1676_CR40","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/bjd.13932","volume":"173","author":"K Papp","year":"2015","unstructured":"Papp K, Tha\u00e7i D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase\u00a0IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173:930\u20139. https:\/\/doi.org\/10.1111\/bjd.13932.","journal-title":"Br J Dermatol"},{"key":"1676_CR41","first-page":"63","volume":"17","author":"JG Vasquez","year":"2024","unstructured":"Vasquez JG, Heim JM, Bhutani T, et al. Improvement in patient-reported symptoms and satisfaction with tildrakizumab in a real-world study in patients with moderate-to-severe plaque psoriasis. J Clin Aesthet Dermatol. 2024;17:63\u20137.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1676_CR42","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1348\/014466505X29657","volume":"44","author":"JD Henry","year":"2005","unstructured":"Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample. Br J Clin Psychol. 2005;44:227\u201339. https:\/\/doi.org\/10.1348\/014466505X29657.","journal-title":"Br J Clin Psychol"},{"key":"1676_CR43","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.37702","volume":"15","author":"A Hepat","year":"2023","unstructured":"Hepat A, Chakole S, Rannaware A. Psychological well-being of adult psoriasis patients: a narrative review. Cureus. 2023;15:e37702. https:\/\/doi.org\/10.7759\/cureus.37702.","journal-title":"Cureus"},{"key":"1676_CR44","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10935-024-00784-0","volume":"45","author":"N Salari","year":"2024","unstructured":"Salari N, Heidarian P, Hosseinian-Far A, Babajani F, Mohammadi M. Global prevalence of anxiety, depression, and stress among patients with skin diseases: a systematic review and meta-analysis. J Prev. 2024;45:611\u201349. https:\/\/doi.org\/10.1007\/s10935-024-00784-0.","journal-title":"J Prev"},{"key":"1676_CR45","doi-asserted-by":"publisher","DOI":"10.33590\/emjdermatol\/10308846","author":"J Taylor","year":"2023","unstructured":"Taylor J. A new landmark for wellbeing in psoriasis: the POSITIVE study. EMJ Dermatol. 2023. https:\/\/doi.org\/10.33590\/emjdermatol\/10308846.","journal-title":"EMJ Dermatol"},{"key":"1676_CR46","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/08039488.2023.2202637","volume":"77","author":"SB Moeller","year":"2023","unstructured":"Moeller SB, Gondan M, Austin SF, Slade M, Simonsen S. National norms of mental health for Denmark. Nord J Psychiatry. 2023;77:617\u201323. https:\/\/doi.org\/10.1080\/08039488.2023.2202637.","journal-title":"Nord J Psychiatry"},{"key":"1676_CR47","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1200\/JCO.2010.34.0331","volume":"30","author":"CJ Hoffman","year":"2012","unstructured":"Hoffman CJ, Ersser SJ, Hopkinson JB, Nicholls PG, Harrington JE, Thomas PW. Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage\u00a00 to III breast cancer: a randomized, controlled trial. J Clin Oncol. 2012;30:1335\u201342. https:\/\/doi.org\/10.1200\/JCO.2010.34.0331.","journal-title":"J Clin Oncol"},{"key":"1676_CR48","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1007\/s12325-025-03266-9","volume":"42","author":"A Domenech","year":"2025","unstructured":"Domenech A, Kasujee I, Koscielny V, Griffiths CEM. Systematic review of the use of the WHO-5 well-being index across different disease areas. Adv Ther. 2025;42:3657\u201377. https:\/\/doi.org\/10.1007\/s12325-025-03266-9.","journal-title":"Adv Ther"},{"key":"1676_CR49","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/bjd\/ljac132","volume":"188","author":"EI Adesanya","year":"2023","unstructured":"Adesanya EI, Matthewman J, Schonmann Y, et al. Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2023;188:460\u201370. https:\/\/doi.org\/10.1093\/bjd\/ljac132.","journal-title":"Br J Dermatol"},{"key":"1676_CR50","doi-asserted-by":"publisher","first-page":"875","DOI":"10.16899\/jcm.962932","volume":"11","author":"B Tuman","year":"2021","unstructured":"Tuman B, \u015eerefli\u0307Can B, Tuman TC. Assessment of anxiety, depression, social anxiety, anxiety sensitivity, and perceived stress in psoriasis patients: a controlled cross-sectional study. J Contemp Med. 2021;11:875\u201382. https:\/\/doi.org\/10.16899\/jcm.962932.","journal-title":"J Contemp Med"},{"key":"1676_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000492784","volume":"235","author":"W Jin","year":"2019","unstructured":"Jin W, Zhang S, Duan Y. Depression symptoms predict worse clinical response to etanercept treatment in psoriasis patients. Dermatology. 2019;235:55\u201364. https:\/\/doi.org\/10.1159\/000492784.","journal-title":"Dermatology"},{"key":"1676_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/life13051219","volume":"13","author":"T-L Timis","year":"2023","unstructured":"Timis T-L, Beni L, Mocan T, Florian I-A, Orasan R-I. Biologic therapies decrease disease severity and improve depression and anxiety symptoms in psoriasis patients. Life Basel. 2023;13:1219. https:\/\/doi.org\/10.3390\/life13051219.","journal-title":"Life Basel"},{"key":"1676_CR53","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13555-020-00428-1","volume":"10","author":"J-P Lacour","year":"2020","unstructured":"Lacour J-P, Bewley A, Hammond E, et al. Association between patient- and physician-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with biologics in real life (PSO-BIO-REAL). Dermatol Ther Heidelb. 2020;10:1099\u2013109. https:\/\/doi.org\/10.1007\/s13555-020-00428-1.","journal-title":"Dermatol Ther Heidelb"},{"key":"1676_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/pde.14892","volume":"39","author":"AA Hebert","year":"2022","unstructured":"Hebert AA, Bobonich MA, Rodriguez Capriles C, et al. Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis. Pediatr Dermatol. 2022;39:55\u201360. https:\/\/doi.org\/10.1111\/pde.14892.","journal-title":"Pediatr Dermatol"},{"key":"1676_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14010223","volume":"14","author":"G Licata","year":"2025","unstructured":"Licata G, Di Brizzi EV, Castelli F, et al. Tildrakizumab and quality of life: deep dive into the impact of psoriasis and treatment on different domains-should psychosocial life impairment be considered a comorbidity? J Clin Med. 2025;14:223. https:\/\/doi.org\/10.3390\/jcm14010223.","journal-title":"J Clin Med"},{"key":"1676_CR56","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/ijd.13956","volume":"57","author":"TJ Stewart","year":"2018","unstructured":"Stewart TJ, Tong W, Whitfeld MJ. The associations between psychological stress and psoriasis: a systematic review. Int J Dermatol. 2018;57:1275\u201382. https:\/\/doi.org\/10.1111\/ijd.13956.","journal-title":"Int J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01676-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01676-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01676-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:06:43Z","timestamp":1774372003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01676-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1676"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01676-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Emanuele Trovato has nothing to disclose; Claudio Bonifati has received support for consulting fees, honoraria, and support for attending meetings from AbbVie, Lilly, Janssen-Cilag, Novartis, and Amgen; Simone Ribero has received research grants, travel support, and consultancy fees from AbbVie, Almirall, Leo Pharma, Johnson & Johnson, L\u2019Or\u00e9al, Sanofi, Sandoz, UCB, Eli Lilly, Novartis, and Bristol Myers Squibb; Massimiliano Scalvenzi has nothing to disclose; Alessandra Narcisi has served on advisory boards and has received honoraria for lectures and research grants from Almirall, AbbVie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme, Amgen, and Boehringer Ingelheim; Aldo Cuccia has nothing to disclose; Vincenzo Panasiti has nothing to disclose; Antonio Giovanni Richetta has nothing to disclose; Gianluca Pagnanelli has no financial disclosures regarding the study; Ketty Peris has received support for consulting fees and honoraria from AbbVie, Almirall, Biogen, Celgene, Janssen, Galderma, Novartis, Lilly, Pierre Fabre, Sandoz, Sanofi, and Sun Pharma; Franco Rongioletti has nothing to disclose; Francesca Satolli has nothing to disclose; Federico Bardazzi has been a consultant, adviser, and clinical study investigator for Eli Lilly, AbbVie, Novartis, Leo Pharma, Sandoz, Bristol Myers Squibb, Abiogen Pharma, Celgene, and Janssen; Alessandro Borghi has nothing to disclose; Carlo Carrera has served as a board participant or speaker for AbbVie, Lilly, Janssen, Novartis, Celgene, Almirall, and Leo Pharma; Marco Galluzzo declares to have acted as speaker and\/or consultant for AbbVie, Almirall, Eli Lilly, Johnson & Johnson, LEO Pharma, Novartis, and Sanofi, outside the submitted work; Claudia Lasagni declares a conflict of interest with AbbVie, Novartis, Lilly, and Almirall; Giovanna Moretti has nothing to disclose; Marco Romanelli has nothing to disclose; Emanuele Cozzani has acted as a speaker for AbbVie, Almirall, Eli Lilly, and Novartis; Claudio Guarneri has been a scientific consultant, speaker, and\/or clinical study investigator for AbbVie, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, Sanofi, Almirall, and Leo Pharma; Marina Venturini has served as advisory board member and\/or consultant and has received fees and speaker\u2019s honoraria and\/or has participated in clinical trials for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Galderma, Janssen, Leo Pharma, Novartis, Pierre Fabre, and UCB Pharma; Maria Rita Bongiorno has nothing to disclose; Francesca Prignano has served as advisory board member and consultant and has received fees and speaker\u2019s honoraria or has participated in clinical trials for AbbVie, Almirall, Leo Pharma, Eli Lilly, Janssen, Novartis, Biogen, Sanofi Genzyme, UCB, and Boehringer Ingelheim; Vito Di Lernia has served as consultant and\/or member of Data Safety Monitoring Boards or advisory boards and\/or has received speaker honoraria from AbbVie, Amgen, Eli Lilly, Janssen, and Novartis; Franca Taviti has nothing to disclose; Severino Persechino has nothing to disclose; Rocco De Pasquale has nothing to disclose; Fabrizio Colonna has received fees from Almirall for conference and scientific consultancy; Marina Talamonti declares to have acted as speaker and\/or consultant for AbbVie, Almirall, Eli Lilly, Johnson & Johnson, LEO Pharma, Novartis, and Sanofi; Antonio Costanzo has served as advisory board member and consultant and has received fees and speaker\u2019s honoraria or participated in clinical trials for AbbVie, Almirall, Biogen, LEO Pharma, Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study followed Guidelines for Good Pharmacoepidemiology Practices of the International Society for Pharmacoepidemiology (ISPE 2016), the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines, the ethical principles laid down in the Declaration of Helsinki, and the Italian AIFA Guidelines for the classification and management of observational studies on drugs. Ethical approval was obtained from the independent ethics committee at each study site. All patients provided written informed consent prior to enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}